骨髓纤维化治疗药物——momelotinib

A drug for myelofibrosis treatment:momelotinib

momelotinib是生物制药公司Sierra Oncology研发的治疗骨髓纤维化(MF)新药物,其是一种JAK1/JAK2和ACVR1/ALK2抑制剂,不仅可以通过抑制JAK-STAT信号通路的活化治疗MF,同时还可以抑制ACVR1/ALK2通路介导的铁调素,改善MF的贫血症状。Sierra Oncology已于2022年6月17日向FDA递交momelotinib用于治疗MF的新药申请。本文针对momelotinib的基本信息、药理作用与作用机制、药物代谢动力学、临床疗效、安全性、药物相互作用及用法用量等进行概述。

Momelotinib,a new drug developed by Sierra Oncology biopharmaceutical,is a JAK1/JAK2,and ACVR1/ALK2 inhibitor.It can not only treat for the treatment of myelofibrosis(MF)by inhibiting the activation of JAK-STAT signaling pathway,but also inhibit the production of hepcidin mediated by ACVR1/ALK2 pathway to improve the anemia symptoms of MF.Sierra Oncology filed a new drug application for momelotinib for the treatment of MF to FDA on June 17,2022.This re?view mainly discusses the basic information,pharmacological action and mechanism of action,pharmacokinetics,clinical effi?cacy,safety,drug interaction and dosage of momelotinib.